AlphAIalphai — Financial news for AI agents
benzinga.comAUG 202 min read$AUPH

Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug - Aurinia Pharmaceuticals

Aurinia Pharmaceuticals (AUPH) settled a patent dispute with Teva (TEVA), with Teva agreeing to not launch its generic voclosporin product until Dec. 7, 2036. Aurinia's Lupkynis is the first FDA-approved oral therapy for lupus nephritis. AUPH shares rose 2.66% premarket to $16.60, trading above its 20-day SMA of $15.31.

Original reporting
benzinga.com
Published Aug 20, 2026, 1:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 20, 2026, 4:47 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug - Aurinia Pharmaceuticals — source image
Source · benzinga.com
Decision brief

The 30-second read

$AUPHBullishMed
01

Why it matters

The settlement is a positive catalyst, reducing near-term revenue dilution risk.

02

Market read

Legal settlement news provides a fresh, material catalyst for AUPH, influencing trader decisions.

03

What to watch

Potential regulatory scrutiny of the settlement terms could introduce risk.

Relevance 7/10Novelty 7/10Timing: premarket today

Background

Aurinia's Lupkynis is the only approved oral therapy for lupus nephritis; the settlement delays generic competition.

Company-level read

Ticker impact

$AUPHBullishHigh confidence
Context

Aurinia settled a patent dispute with Teva, securing enforceability of its voclosporin patents and delaying generic entry until Dec 7, 2036.

Expected impact

Potential upside of 5-10% as investors price in delayed generic launch.

Evidence & confidence

Legal protection of patents extends market exclusivity, a material catalyst for a biotech with limited pipeline.

Market effects

Sector

May boost confidence in other biotech firms with pending patent litigations.

Regional

Limited to US biotech sector.

Global

Minimal beyond niche pharma investors.

Counterpoint

What could challenge this read

If Teva successfully challenges the patents later, generic entry could occur sooner, negating the upside.

Key entities

  • Company
    Aurinia Pharmaceuticals

    Biopharma developing Lupkynis (voclosporin).

  • Company
    Teva Pharmaceutical Industries

    Generic drug manufacturer seeking to launch a generic version of voclosporin.

Read at source← All news

Related articles

AUG 20
$AUPHMed

Aurinia Pharmaceuticals (AUPH) Secures Patent Settlement With Teva, Blocking Lupkynis Generic Until 2036

Aurinia Pharmaceuticals (AUPH) settled a patent dispute with Teva (TEVA), delaying a generic version of Lupkynis until 2036. The deal boosted AUPH shares by 7%. Aurinia also settled with Sun Pharma in 2023 and faces ongoing litigation with other generics makers. Lupkynis is Aurinia's sole marketed drug, with H1 2026 revenue up 21% YoY to $161M, and full-year guidance of $315M-$325M.

londoninsider.co.uk2 min
AUG 20
$AUPHMed

Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises

Aurinia Pharmaceuticals settled patent litigation with Teva, pushing back potential generic competition for voclosporin until 2036. Aurinia's stock rose 6% on the news. Lupkynis, Aurinia's voclosporin product, recorded $153M in sales in H1 2026, up 21% YoY. Aurinia's patent litigation with other companies continues.

zacks.com2 min
AUG 19
$AUPHMed

Aurinia Settles Patent Litigation with Teva

Aurinia Pharmaceuticals (AUPH) settled patent litigation with Teva, which agreed to not launch its generic voclosporin product until December 7, 2036, unless certain conditions are met. Teva acknowledged the validity of Aurinia's patents, which expire in December 2037. Aurinia's litigation against other companies continues.

leaderpost.com2 min
AUG 19
$AUPHMed

Aurinia stock falls on Teva patent settlement for voclosporin

Aurinia Pharmaceuticals (AUPH) shares fell 2% after announcing a patent settlement with Teva (TEVA) for generic voclosporin, allowing Teva to launch its version no earlier than 2036. The agreement validates Aurinia's patents and resolves litigation. Voclosporin is marketed as LUPKYNIS for lupus nephritis. Aurinia continues patent actions against other companies.

investing.com4 min
AUG 6
$AUPHMed

Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q2 and first-half 2026 results. Total revenue rose to $83.2M and $160.9M, and net product sales of LUPKYNIS increased to $79.4M and $153.0M. Net income was $37.4M and $71.8M. Cash and investments were $443.1M at June 30, 2026. 2026 guidance: revenue $315M-$325M, net product sales $305M-$315M. It also initiated the PRESERVE Phase 4 study of LUPKYNIS plus biologics.

thestarphoenix.com5 min